-
Mashup Score: 2Illuminating a Potential Culprit in Melanoma Treatment Resistance - 1 month(s) ago
Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1MIA Calculator for Predicting Recurrence-Free and Overall Survival in Stage II Melanoma - The ASCO Post - 3 month(s) ago
In a study reported in the Journal of Clinical Oncology, Varey et al developed the Melanoma Institute Australia (MIA) calculator for predicting recurrence-free and overall survival in stage II melanoma and found that it outperformed modeling based on American Joint Committee on Cancer (AJCC)-8th edition melanoma staging. The study involved data on 3,220 patients from the MIA database diagnosed with clinical or pathologic stage II melanoma. Prediction models were developed using multivariate Cox regression
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Three-Year Overall Survival with Tebentafusp in Previously Untreated Advanced Uveal Melanoma - The ASCO Post - 7 month(s) ago
In an analysis presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA50) and reported in The New England Journal of Medicine by Jessica C. Hassel, MD, and colleagues, overall survival at 3 years in the phase III IMCgp100-202 trial continued to favor teben tafusp-tebn over investigator’s choice of treatment in previously untreated patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma. In the open-label international trial, 378 patients enrolled
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Illuminating a Potential Culprit in Melanoma Treatment Resistance https://t.co/GuEMvansHJ #melsm #melanoma #oncology